Appello Pharmaceuticals is a preclinical-stage company focused on CNS disorders.
Appello Pharmaceuticals has raised $13.5M in total funding. The most recent round was Series B. The last funding was announced in January 2022.
Appello Pharmaceuticals's investors include Deerfield, Mountain Group Capital.
Appello Pharmaceuticals is headquartered in Nashville, United States.
Appello Pharmaceuticals is a preclinical-stage company focused on CNS disorders.
Appello Pharmaceuticals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Appello Pharmaceuticals — Funding & Investors." VCBacked, January 24, 2022, https://www.vcbacked.co/company/appello-pharmaceuticals. Accessed October 4, 2026.
VCBacked. (2022). Appello Pharmaceuticals — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/appello-pharmaceuticals
{{cite web |title=Appello Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/appello-pharmaceuticals |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated